Skip to main content
main-content

01.09.2009 | Retinal Disorders | Ausgabe 9/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009

Intravitreal bevacizumab for CNV-complicated tilted disk syndrome

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 9/2009
Autoren:
Paolo Milani, Alfredo Pece, Giuseppe Moretti, Pruneri Lino, Antonio Scialdone

Abstract

Background

Tilted disc syndrome is a congenital anomaly characterized by an inferonasal “tilting” of the optic disc. We report three patients affected by macular neovascularisation-complicated tilted disk syndrome treated by intravitreal bevacizumab.

Methods

Three interventional case reports are hereby documented. Ophthalmic evaluations were registered, including monthly visual acuity examination, OCT and fluorescein angiography before and after consecutive intravitreal injection of 1.25 mg bevacizumab (0.05 ml, Avastin).

Results

All patients, aged more than 65 years, experienced decreased visual acuity after an observation period of 6 (two patients) and 3 months (one patient). Angiographic leakage with neuroretinal rarefaction and RPE/choriocapillary complex elevation at OCT remained persistent in two patients and reduced in one.

Conclusions

No benefit in terms of visual acuity was noted after intravitreal bevacizumab treatments. Larger studies should be conducted to confirm our small series observation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

15.06.2018 | Video plus | Ausgabe 7/2018

Diakaustische Kammerwinkeluntersuchung

Videobeitrag

01.06.2018 | themenschwerpunkt | Ausgabe 3/2018

Das Kind in der Kunst

22.05.2018 | Das Frühgeborene | Leitthema | Ausgabe 6/2018

Frühgeborenenretinopathie in welchem Stadium wie behandeln?

Aktueller Wissensstand und Ausblick